AstraZeneca has managed to secure a temporary injunction stopping Actavis from distributing its generic version of the asthma drug Pulmicort Repsules, which was launched at the end of last week.

The Anglo-Swedish drugmaker made its legal move after a US court confirmed that a key patent on Pulmicort Repsules (budesonide) was invalid (see link below for full story). Now the US Court of Appeals for the Federal Circuit has issued a temporary injunction to prevent Actavis from further distribution of its copy until the matter is settled.

Actavis noted that “the temporary injunction does not address product shipped prior to its issuance”. For the 12 months ended June 30, 2014, total US brand and generic sales of Pulmicort Respules (Teva sells an authorised generic) were approximately $1.1 billion.